Spectrum Gears Up To File Rolontis, Stresses Patient Access
Biosimilars of Amgen's blockbuster Neulasta pose a competitive threat to long-acting GSF Rolontis, but the company has experience with group purchasing and notes that large oncology clinics will make more revenue by providing higher-priced products.
You may also be interested in...
Keeping Track: Two Goal Date Extensions, Another Herceptin Biosimilar Approval, And A BLA Withdrawal
The latest drug development news and highlights from our US FDA Performance Tracker.
By selling seven approved oncology/hematology products to a US affiliate of Aurobindo, Spectrum gets cash to increase focus on late-stage candidates Rolontis for neutropenia and poziotinib for solid tumors.
2019 could be a monumental year for the South Korean pharma industry, as several new drug assets await the green light from the US FDA.